title: Synthesis of novel GABA uptake inhibitors. Part 6: preparation and evaluation of N-Omega asymmetrically substituted nipecotic acid derivatives.
abstract: In a previous series of potent GABA uptake inhibitors published from this laboratory, we noticed that asymmetry in the substitution pattern of the bis-aromatic moiety in known GABA uptake inhibitors such as 4 [1-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylic acid] and 5 [(R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid] was beneficial for high affinity. This led us to investigate asymmetric analogues of known symmetric GABA uptake inhibitors in which one of the aryl groups has been exchanged with an alkyl, alkylene or cycloalkylene moiety as well as other modifications in the lipophilic part. The in vitro values for inhibition of [(3)H]-GABA uptake in rat synaptosomes was determined for each compound, and it was found that several of the novel compounds inhibit GABA uptake as potently as their known symmetrical reference analogues. Several of the novel compounds were also evaluated for their ability to inhibit clonic seizures induced by a 15 mg/kg (ip) dose of methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) in vivo. Some of the compounds, for example 18 [(R)-1-(2-(((1,2-bis(2-fluorophenyl)ethylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid], show a high in vivo potency and protective index comparable with that of our recently launched anticonvulsant product, 5 [(R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid], and may therefore serve as second-generation drug candidates.
authors.affiliation: Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK 2760, Måløv, Denmark. kea@novonordisk.com
authors.forename: K E
authors.initials: KE
authors.lastname: Andersen
authors.forename: J
authors.initials: J
authors.lastname: Lau
authors.forename: B F
authors.initials: BF
authors.lastname: Lundt
authors.forename: H
authors.initials: H
authors.lastname: Petersen
authors.forename: P O
authors.initials: PO
authors.lastname: Huusfeldt
authors.forename: P D
authors.initials: PD
authors.lastname: Suzdak
authors.forename: M D
authors.initials: MD
authors.lastname: Swedberg
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004987:Ethers; D018756:GABA Antagonists / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D009557:Nipecotic Acids / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology*; D010091:Oximes; D051381:Rats; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D013329:Structure-Activity Relationship; D013574:Synaptosomes / Q000378:metabolism; D014316:Tritium; D005680:gamma-Aminobutyric Acid / Q000187:drug effects / Q000493:pharmacokinetics
chemical_list: D004987:Ethers; D018756:GABA Antagonists; D009557:Nipecotic Acids; D010091:Oximes; D014316:Tritium; D005680:gamma-Aminobutyric Acid